To examine algino-oligosaccharide production by alginase from newly isolated Flavobacterium sp. LXA and its elicitor and antibacterial activity. Algino-oligosaccharide production from alginate was ...carried out using alginase obtained from a newly isolated Flavobacterium sp. LXA. When alginase was partially purified by dual ammonium sulfate precipitation and used for alginate degradation, the viscosity loss correlated well with the release of reducing terminals. The optimal temperature and pH for alginate degradation was 40°C and pH 7·0, respectively. When alginate was added at an initial concentration of more than 0·8%, the maximal degradation rate of alginate was obtained. Under these optimal reaction conditions and with partially purified alginase, the average degrees of polymerization (DP) of alginate-degraded products was about 6·0, which favoured algino-oligosaccharide production. The algino-oligosaccharides showed an elicitor activity stimulating the accumulation of phytoalexin and inducing phenylalanine ammonia lyase in soybean cotyledon, and antimicrobial activity on Pseudomonas aeruginosa. Algino-oligosaccharide could be degraded from alginate by the partially purified alginase and its maximal bioactivity occurred on the oligosaccharide with average DP 6·8. Algino-oligosaccharide was first reported to have elicitor and antibacterial activity and have potential as a biological agent for protection against plant or human disease.
The influence of the Dzyaloshinskii-Moriya interaction on the spin-wave dispersion in an Fe double layer grown on W(110) is measured for the first time. It is demonstrated that the ...Dzyaloshinskii-Moriya interaction breaks the degeneracy of spin waves and leads to an asymmetric spin-wave dispersion relation. An extended Heisenberg spin Hamiltonian is employed to obtain the longitudinal component of the Dzyaloshinskii-Moriya vectors from the experimentally measured energy asymmetry.
ABSTRACT We present preliminary results of the quasar survey in the Large Sky Area Multi-Object Fiber Spectroscopic Telescope (LAMOST) first data release (DR1), which includes the pilot survey and ...the first year of the regular survey. There are 3921 quasars reliably identified, among which 1180 are new quasars discovered in the survey. These quasars are at low to median redshifts, with a highest z of 4.83. We compile emission line measurements around the H , Hβ, Mg ii, and C iv regions for the new quasars. The continuum luminosities are inferred from SDSS photometric data with model fitting, as the spectra in DR1 are non-flux-calibrated. We also compile the virial black hole mass estimates, with flags indicating the selection methods, and broad absorption line quasars. The catalog and spectra for these quasars are also available. Of the 3921 quasars, 28% are independently selected with optical-infrared colors, indicating that the method is quite promising for the completeness of the quasar survey. LAMOST DR1 and the ongoing quasar survey will provide valuable data for studies of quasars.
The celebrated Cheeger’s Inequality (Alon and Milman 1985; Alon 1986) establishes a bound on the edge expansion of a graph via its spectrum. This inequality is central to a rich spectral theory of ...graphs, based on studying the eigenvalues and eigenvectors of the adjacency matrix (and other related matrices) of graphs. It has remained open to define a suitable spectral model for hypergraphs whose spectra can be used to estimate various combinatorial properties of the hypergraph.
In this article, we introduce a new hypergraph Laplacian operator generalizing the Laplacian matrix of graphs. In particular, the operator is induced by a diffusion process on the hypergraph, such that within each hyperedge, measure flows from vertices having maximum weighted measure to those having minimum. Since the operator is nonlinear, we have to exploit other properties of the diffusion process to recover the Cheeger’s Inequality that relates hyperedge expansion with the “second eigenvalue” of the resulting Laplacian. However, we show that higher-order spectral properties cannot hold in general using the current framework.
Since higher-order spectral properties do not hold for the Laplacian operator, we instead use the concept of procedural minimizers to consider higher-order Cheeger-like inequalities. For any
k
∈ N, we give a polynomial-time algorithm to compute an
O
(log
r
)-approximation to the
k
th procedural minimizer, where
r
is the maximum cardinality of a hyperedge. We show that this approximation factor is optimal under the SSE hypothesis (introduced by Raghavendra and Steurer (2010)) for constant values of
k
.
Moreover, using the factor-preserving reduction from vertex expansion in graphs to hypergraph expansion, we show that all our results for hypergraphs extend to vertex expansion in graphs.
Protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme that mainly represses transcription of target genes via symmetric dimethylation of arginine residues on histones H4R3, ...H3R8 and H2AR3. Accumulating evidence suggests that PRMT5 may function as an oncogene to drive cancer cell growth by epigenetic inactivation of several tumor suppressors. Here, we provide evidence that PRMT5 promotes prostate cancer cell growth by epigenetically activating transcription of the androgen receptor (AR) in prostate cancer cells. Knockdown of PRMT5 or inhibition of PRMT5 by a specific inhibitor reduces the expression of AR and suppresses the growth of multiple AR-positive, but not AR-negative, prostate cancer cells. Significantly, knockdown of PRMT5 in AR-positive LNCaP cells completely suppresses the growth of xenograft tumors in mice. Molecular analysis reveals that PRMT5 binds to the proximal promoter region of the AR gene and contributes mainly to the enriched symmetric dimethylation of H4R3 in the same region. Mechanistically, PRMT5 is recruited to the AR promoter by its interaction with Sp1, the major transcription factor responsible for AR transcription, and forms a complex with Brg1, an ATP-dependent chromatin remodeler, on the proximal promoter region of the AR gene. Furthermore, PRMT5 expression in prostate cancer tissues is significantly higher than that in benign prostatic hyperplasia tissues, and PRMT5 expression correlates positively with AR expression at both the protein and mRNA levels. Taken together, our results identify PRMT5 as a novel epigenetic activator of AR in prostate cancer. Given that inhibiting AR transcriptional activity or androgen synthesis remains the major mechanism of action for most existing anti-androgen agents, our findings also raise an interesting possibility that targeting PRMT5 may represent a novel approach for prostate cancer treatment by eliminating AR expression.
Complex motor commands for human locomotion are generated through the combination of motor modules representable as muscle synergies. Recent data have argued that muscle synergies are inborn or ...determined early in life, but development of the neuro-musculoskeletal system and acquisition of new skills may demand fine-tuning or reshaping of the early synergies. We seek to understand how locomotor synergies change during development and training by studying the synergies for running in preschoolers and diverse adults from sedentary subjects to elite marathoners, totaling 63 subjects assessed over 100 sessions. During development, synergies are fractionated into units with fewer muscles. As adults train to run, specific synergies coalesce to become merged synergies. Presences of specific synergy-merging patterns correlate with enhanced or reduced running efficiency. Fractionation and merging of muscle synergies may be a mechanism for modifying early motor modules (Nature) to accommodate the changing limb biomechanics and influences from sensorimotor training (Nurture).
Early onset of myopia is associated with high myopia later in life, and myopia is irreversible once developed.
To evaluate the efficacy of low-concentration atropine eyedrops at 0.05% and 0.01% ...concentration for delaying the onset of myopia.
This randomized, placebo-controlled, double-masked trial conducted at the Chinese University of Hong Kong Eye Centre enrolled 474 nonmyopic children aged 4 through 9 years with cycloplegic spherical equivalent between +1.00 D to 0.00 D and astigmatism less than -1.00 D. The first recruited participant started treatment on July 11, 2017, and the last participant was enrolled on June 4, 2020; the date of the final follow-up session was June 4, 2022.
Participants were assigned at random to the 0.05% atropine (n = 160), 0.01% atropine (n = 159), and placebo (n = 155) groups and had eyedrops applied once nightly in both eyes over 2 years.
The primary outcomes were the 2-year cumulative incidence rate of myopia (cycloplegic spherical equivalent of at least -0.50 D in either eye) and the percentage of participants with fast myopic shift (spherical equivalent myopic shift of at least 1.00 D).
Of the 474 randomized patients (mean age, 6.8 years; 50% female), 353 (74.5%) completed the trial. The 2-year cumulative incidence of myopia in the 0.05% atropine, 0.01% atropine, and placebo groups were 28.4% (33/116), 45.9% (56/122), and 53.0% (61/115), respectively, and the percentages of participants with fast myopic shift at 2 years were 25.0%, 45.1%, and 53.9%. Compared with the placebo group, the 0.05% atropine group had significantly lower 2-year cumulative myopia incidence (difference, 24.6% 95% CI, 12.0%-36.4%) and percentage of patients with fast myopic shift (difference, 28.9% 95% CI, 16.5%-40.5%). Compared with the 0.01% atropine group, the 0.05% atropine group had significantly lower 2-year cumulative myopia incidence (difference, 17.5% 95% CI, 5.2%-29.2%) and percentage of patients with fast myopic shift (difference, 20.1% 95% CI, 8.0%-31.6%). The 0.01% atropine and placebo groups were not significantly different in 2-year cumulative myopia incidence or percentage of patients with fast myopic shift. Photophobia was the most common adverse event and was reported by 12.9% of participants in the 0.05% atropine group, 18.9% in the 0.01% atropine group, and 12.2% in the placebo group in the second year.
Among children aged 4 to 9 years without myopia, nightly use of 0.05% atropine eyedrops compared with placebo resulted in a significantly lower incidence of myopia and lower percentage of participants with fast myopic shift at 2 years. There was no significant difference between 0.01% atropine and placebo. Further research is needed to replicate the findings, to understand whether this represents a delay or prevention of myopia, and to assess longer-term safety.
Chinese Clinical Trial Registry: ChiCTR-IPR-15006883.
We present lattice QCD results for masses and magnetic polarizabilities of light and strange pseudoscalar mesons, chiral condensates, decay constants of neutral pion, and neutral kaon in the presence ...of background magnetic fields with e B ranging up to around 3.35 GeV2( ~ 70 M2π) in the vacuum. The computations were carried out in (2 + 1)-flavor QCD mostly on 323 × 96 lattices using the highly improved staggered quark action with Mπ ≈ 220 MeV at zero temperature. We find that the masses of neutral pseudoscalar mesons monotonously decrease as the magnetic field strength grows and then saturate at a nonzero value, while there exists a nonmonotonous behavior of charged pion and kaon masses in the magnetic field. We observe a qB scaling of the up and down quark flavor components of neutral pion mass, neutral pion decay constant as well as the quark chiral condensates at 0.05 ≲ eB ≲ 3.35 GeV2. We show that the correction to the Gell-Mann-Oakes-Renner relation involving the neutral pion is less than 6% and the correction for the relation involving neutral kaon is less than 30% at e B ≲ 3.35 GeV2 . We also derive the Ward-Takahashi identities for QCD in the magnetic field in the continuum formulation including the relation between integrated neutral pseudoscalar meson correlators and chiral condensates.
PDF
